Elevated carbohydrate antigen 125 (CA125) is associated with incident heart failure and mortality in acute coronary syndrome

Author:

Yndigegn Troels12,Gu Thomas3,Grufman Helena4,Erlinge David12,Mokhtari Arash12,Ekelund Ulf5,Magnusson Martin46,Gustafsson Emma4,Nilsson Jan4,Goncalves Isabel46,Schiopu Alexandru378

Affiliation:

1. Department of Clinical Sciences Lund Lund University Lund Sweden

2. Department of Cardiology Skåne University Hospital Lund Lund Sweden

3. Department of Translational Medicine Lund University Lund Sweden

4. Department of Clinical Sciences Malmö Lund University Malmö Sweden

5. Department of Emergency Medicine Skåne University Hospital Lund Lund Sweden

6. Department of Cardiology Skåne University Hospital Malmö Malmö Sweden

7. Department of Internal Medicine Skåne University Hospital Lund Lund Sweden

8. Nicolae Simionescu Institute of Cellular Biology and Pathology Bucharest Romania

Abstract

AbstractAimsCarbohydrate antigen 125 (CA125), a mucin produced by serosal cells in response to mechanical and inflammatory stimuli, has emerged as an important biomarker to guide risk stratification in heart failure (HF). The prognostic value of CA125 in acute coronary syndrome (ACS) patients is less explored.MethodsIn a cohort of 524 ACS patients (73% males, mean age 67 ± 12 years), we assessed the associations between CA125 and the risk for HF and death during a median follow‐up period of 27.3 months for incident HF and 39.5 months for mortality. Plasma CA125 was measured within 24 h after admission in the entire cohort and after 6 weeks in a subgroup of 115 elderly patients (>75 years of age). We also assessed the relationships between baseline CA125 and echocardiographic parameters of cardiac structure and function at 1 year post‐ACS in this subgroup.ResultsBaseline CA125 was associated with incident HF in the entire cohort in a Cox proportional hazards model adjusted for age, sex, cardiovascular (CV) risk factors (diabetes, smoking, hypertension, previous HF, previous ACS and previous stroke), renal function and revascularization {hazard ratio [HR] 1.46 [95% confidence interval (CI) 1.10–1.93] per 1‐standard deviation [SD] CA125 increase; P = 0.009}. In the detailed follow‐up subgroup, elevated baseline CA125 predicted subsequent deterioration of left ventricular (LV) ejection fraction (LVEF), defined as a >5% absolute LVEF decrease in patients with LVEF ≥ 50% at discharge [odds ratio (OR) 3.31 (95% CI 1.15–9.54) per 1‐SD baseline CA125 increase; P = 0.027]. We also found significant correlations between high baseline CA125 and larger LV volumes (LV end‐diastolic volume index, Spearman's r = 0.329, P < 0.001; LV end‐systolic volume index, r = 0.391, P < 0.001) and left atrial volume index (r = 0.320, P < 0.001) at 1 year post‐ACS, indicative of adverse cardiac remodelling. Elevated baseline and follow‐up CA125 were associated with increased mortality, independently of age and sex [HR 1.37 (95% CI 1.09–1.71), P = 0.006, per 1‐SD baseline CA125; HR 1.98 (95% CI 1.06–3.67), P = 0.031, per increasing 6 week CA125 tertile]. The relationship between 6 week CA125 and incident mortality remained significant in the fully adjusted model [HR 2.23 (95% CI 1.15–4.35) per increasing CA125 tertile; P = 0.018].ConclusionsWe report independent associations between elevated CA125, LV dysfunction, cardiac remodelling, incident HF and mortality post‐ACS. Our results warrant further evaluation of CA125 as a potential biomarker for risk stratification and management of ACS patients, both at the time of the acute coronary event and during follow‐up.

Funder

Marcus och Amalia Wallenbergs minnesfond

Hjärt-Lungfonden

Vetenskapsrådet

Svenska Läkaresällskapet

Crafoordska Stiftelsen

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3